Supply and Clinical Application of Actinium-225 and Bismuth-213

Overview

Journal Semin Nucl Med

Specialty Nuclear Medicine

Date 2020 Mar 17

PMID 32172796

Citations 39

Authors

Alfred Morgenstern

Christos Apostolidis

Frank Bruchertseifer

Affiliations

Soon will be listed here.

Abstract

The recent development of Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters Actinium and its daughter nuclide Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with Ac or Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.

Citing Articles

Production and purification of molecular Ac at CERN-ISOLDE.

Au M, Nies L, Stegemann S, Athanasakis-Kaklamanakis M, Cocolios T, Fischer P J Radioanal Nucl Chem. 2025; 334(1):367-379.

PMID: 39901925 PMC: 11787200. DOI: 10.1007/s10967-024-09811-0.

Actinium-225 in Targeted Alpha Therapy.

Rahman A, Babu M, Ovi M, Zilani M, Eithu I, Chakraborty A J Med Phys. 2024; 49(2):137-147.

PMID: 39131433 PMC: 11309130. DOI: 10.4103/jmp.jmp_22_24.

Actinium chelation and crystallization in a macromolecular scaffold.

Wacker J, Woods J, Rupert P, Peterson A, Allaire M, Lukens W Nat Commun. 2024; 15(1):5741.

PMID: 39009580 PMC: 11251196. DOI: 10.1038/s41467-024-50017-5.

Actinium-225 targeted alpha particle therapy for prostate cancer.

Bidkar A, Zerefa L, Yadav S, VanBrocklin H, Flavell R Theranostics. 2024; 14(7):2969-2992.

PMID: 38773983 PMC: 11103494. DOI: 10.7150/thno.96403.

Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?.

Kleynhans J, Ebenhan T, Cleeren F, Sathekge M Eur J Nucl Med Mol Imaging. 2024; 51(7):1965-1980.

PMID: 38676735 PMC: 11139742. DOI: 10.1007/s00259-024-06719-5.

References

Apostolidis C, Molinet R, McGinley J, Abbas K, Mollenbeck J, Morgenstern A . Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2004; 62(3):383-7. DOI: 10.1016/j.apradiso.2004.06.013. View

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M . Safety and efficacy of targeted alpha therapy with Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2018; 46(3):614-622. DOI: 10.1007/s00259-018-4225-7. View

Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J . Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Ac-PSMA-617 Radioligand Therapy. J Nucl Med. 2019; 61(1):62-69. DOI: 10.2967/jnumed.119.229229. View

Morgenstern A, Bruchertseifer F . Development of Targeted Alpha Therapy from Bench to Bedside. J Med Imaging Radiat Sci. 2019; 50(4S1):S18-S20. DOI: 10.1016/j.jmir.2019.06.046. View

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T . Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018; 46(1):129-138. PMC: 6267694. DOI: 10.1007/s00259-018-4167-0. View

Apostolidis C, Molinet R, RASMUSSEN G, Morgenstern A . Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005; 77(19):6288-91. DOI: 10.1021/ac0580114. View

Melville G, Meriarty H, Metcalfe P, Knittel T, Allen B . Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226. Appl Radiat Isot. 2007; 65(9):1014-22. DOI: 10.1016/j.apradiso.2007.03.018. View

Boll R, Malkemus D, Mirzadeh S . Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot. 2005; 62(5):667-79. DOI: 10.1016/j.apradiso.2004.12.003. View

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel F, Haberkorn U . Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J Nucl Med. 2018; 59(5):795-802. DOI: 10.2967/jnumed.117.203539. View

10.

Jurcic J, Larson S, Sgouros G, McDevitt M, Finn R, Divgi C . Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002; 100(4):1233-9. View

11.

Kratochwil C, Bruchertseifer F, Giesel F, Weis M, Verburg F, Mottaghy F . 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016; 57(12):1941-1944. DOI: 10.2967/jnumed.116.178673. View

12.

Raja C, Graham P, Rizvi S, Song E, Goldsmith H, Thompson J . Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2007; 6(6):846-52. DOI: 10.4161/cbt.6.6.4089. View

13.

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M . Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018; 45(9):1636-1644. PMC: 6061489. DOI: 10.1007/s00259-018-4015-2. View

14.

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S . Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010; 37(7):1335-44. DOI: 10.1007/s00259-010-1385-5. View

15.

Kneifel S, Cordier D, Good S, Ionescu M, Ghaffari A, Hofer S . Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res. 2006; 12(12):3843-50. DOI: 10.1158/1078-0432.CCR-05-2820. View

16.

Jurcic J . Targeted Alpha-Particle Therapy for Hematologic Malignancies. J Med Imaging Radiat Sci. 2019; 50(4 Suppl 1):S53-S57. DOI: 10.1016/j.jmir.2019.05.008. View

17.

Kratochwil C, Giesel F, Bruchertseifer F, Mier W, Apostolidis C, Boll R . ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014; 41(11):2106-19. PMC: 4525192. DOI: 10.1007/s00259-014-2857-9. View

18.

Geerlings M, Kaspersen F, Apostolidis C, van der Hout R . The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun. 1993; 14(2):121-5. DOI: 10.1097/00006231-199302000-00009. View

19.

Rosenblat T, McDevitt M, Mulford D, Pandit-Taskar N, Divgi C, Panageas K . Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010; 16(21):5303-11. PMC: 2970691. DOI: 10.1158/1078-0432.CCR-10-0382. View

20.

Allen B, Raja C, Rizvi S, Li Y, Tsui W, Graham P . Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2005; 4(12):1318-24. DOI: 10.4161/cbt.4.12.2251. View